Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)
Phase 2
Completed
- Conditions
- Post-nasal DripRhinorrheaSeasonal Allergic Rhinitis
- Interventions
- Drug: Placebo for Oxybutynin 2.5 mg
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 540
- Registration Number
- NCT00816972
A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 108
- Registration Number
- NCT00812006
A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 244
- Registration Number
- NCT00806416
Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 54
- Registration Number
- NCT00805324
Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 311
- Registration Number
- NCT00805584
A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 318
- Registration Number
- NCT00803790
Montelukast in Chronic Asthma
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2000
- Registration Number
- NCT00802789
An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 51
- Registration Number
- NCT00795522
How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 282
- Registration Number
- NCT00795158
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)
Phase 4
Completed
- Conditions
- Seasonal Allergic RhinitisPerennial Allergic Rhinitis
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 122
- Registration Number
- NCT00794495